R
45.40
-0.07 (-0.15%)
| Penutupan Terdahulu | 45.47 |
| Buka | 45.42 |
| Jumlah Dagangan | 2,518,133 |
| Purata Dagangan (3B) | 4,061,635 |
| Modal Pasaran | 26,259,779,584 |
| Harga / Pendapatan (P/E TTM) | 25.51 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.86 |
| Harga / Jualan (P/S) | 11.08 |
| Harga / Buku (P/B) | 3.09 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Hasil Dividen (DY TTM) | 1.97% |
| Margin Keuntungan | 48.26% |
| Margin Operasi (TTM) | 94.00% |
| EPS Cair (TTM) | 2.45 |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 4,888.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 77.82% |
| Nisbah Semasa (MRQ) | 1.56 |
| Aliran Tunai Operasi (OCF TTM) | 2.70 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -1.36 B |
| Pulangan Atas Aset (ROA TTM) | 7.04% |
| Pulangan Atas Ekuiti (ROE TTM) | 18.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Royalty Pharma plc | Menaik | Menaik |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.50 |
|
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Value |
| % Dimiliki oleh Orang Dalam | 8.92% |
| % Dimiliki oleh Institusi | 79.64% |
| Julat 52 Minggu | ||
| Median | 50.00 (10.13%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 27 Jan 2026 | 50.00 (10.13%) | Beli | 40.74 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| COYNE TERRANCE P. | - | 47.47 | -34,791 | -1,651,529 |
| Jumlah Keseluruhan Kuantiti Bersih | -34,791 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,651,529 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 47.47 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| COYNE TERRANCE P. | Pegawai | 02 Mar 2026 | Jual automatik (-) | 34,791 | 47.47 | 1,651,529 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Jan 2026 | Pengumuman | Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 |
| 12 Jan 2026 | Pengumuman | Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference |
| 11 Jan 2026 | Pengumuman | Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo |
| 11 Jan 2026 | Pengumuman | Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo |
| 09 Jan 2026 | Pengumuman | Royalty Pharma Announces Dividend Increase |
| 29 Dec 2025 | Pengumuman | Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones |
| 16 Dec 2025 | Pengumuman | Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million |
| Hasil Dividen (DY TTM) | 1.97% |
| Purata Hasil Dividen 5T | 2.41% |
| Nisbah Pembayaran | 34.69% |
| Jangkaan Pembayaran Dividen Seterusnya | Jun 2026 |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 20 Feb 2026 | 09 Jan 2026 | 10 Mar 2026 | 0.235 Tunai |
| 14 Nov 2025 | 17 Oct 2025 | 10 Dec 2025 | 0.22 Tunai |
| 15 Aug 2025 | 18 Jul 2025 | 10 Sep 2025 | 0.22 Tunai |
| 16 May 2025 | 21 Apr 2025 | 10 Jun 2025 | 0.22 Tunai |
| 21 Feb 2025 | 09 Jan 2025 | 10 Mar 2025 | 0.22 Tunai |
| 15 Nov 2024 | 11 Oct 2024 | 10 Dec 2024 | 0.21 Tunai |
| 16 Aug 2024 | 17 Jul 2024 | 13 Sep 2024 | 0.21 Tunai |
| 16 May 2024 | 17 Apr 2024 | 14 Jun 2024 | 0.21 Tunai |
| 15 Feb 2024 | 19 Jan 2024 | 15 Mar 2024 | 0.21 Tunai |
| 16 Nov 2023 | 16 Oct 2023 | 15 Dec 2023 | 0.2 Tunai |
| 17 Aug 2023 | 17 Jul 2023 | 15 Sep 2023 | 0.2 Tunai |
| 18 May 2023 | 17 Apr 2023 | 15 Jun 2023 | 0.2 Tunai |
| 15 Feb 2023 | 09 Jan 2023 | 15 Mar 2023 | 0.2 Tunai |
| 17 Nov 2022 | 17 Oct 2022 | 15 Dec 2022 | 0.19 Tunai |
| 18 Aug 2022 | - | 15 Sep 2022 | 0.19 Tunai |
| 19 May 2022 | 18 Apr 2022 | 15 Jun 2022 | 0.19 Tunai |
| 17 Feb 2022 | 06 Jan 2022 | 15 Mar 2022 | 0.19 Tunai |
| 18 Nov 2021 | 15 Oct 2021 | 15 Dec 2021 | 0.17 Tunai |
| 19 Aug 2021 | 16 Jul 2021 | 15 Sep 2021 | 0.17 Tunai |
| 19 May 2021 | 15 Apr 2021 | 15 Jun 2021 | 0.17 Tunai |
| 18 Feb 2021 | 08 Jan 2021 | 15 Mar 2021 | 0.17 Tunai |
| 19 Nov 2020 | 15 Oct 2020 | 15 Dec 2020 | 0.15 Tunai |
| 14 Sep 2020 | 02 Sep 2020 | 30 Sep 2020 | 0.15 Tunai |
| Papar semua | |||
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2026 | 0.235 | 1 | 0.52 |
| 2025 | 0.880 | 4 | 2.28 |
| 2024 | 0.840 | 4 | 3.29 |
| 2023 | 0.800 | 4 | 2.85 |
| 2022 | 0.760 | 4 | 1.92 |
| 2021 | 0.680 | 4 | 1.71 |
| 2020 | 0.300 | 2 | 0.60 |
| Papar semua | |||
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |